The FDA has accepted Apnimed’s NDA for AD109 (aroxybutynin/atomoxetine), a potential first-in-class oral therapy for adults with obstructive sleep apnea.
The American College of Cardiology issued a 2026 scientific statement on direct oral anticoagulants for the prevention of thrombotic events.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results